INTRODUCTION The influence of demographic and clinical factors on the outcome of (131)I therapy in hyperthyroid patients has been examined, based on a retrospective evaluation of results obtained in patients submitted to (131)I treatment at the Department of Nuclear Medicine and Oncological Endocrinology, Medical University of Lodz (Province Hospital, Zgierz). The goal of the study was to analy...

Context The mechanisms of thymic hyperplasia in Graves disease and its involution after radioiodine (I-131) therapy remain unknown. Objective To examine whether computed tomography (CT) findings of the thymus in patients with Graves disease change before and 6 months after I-131 therapy and to elucidate factors that affect these changes. Design Setting A retrospective, single-center study w...

There is no ideal treatment for benign multinodular goitre. Besides surgery, which is recommended for large goitres or when malignancy cannot be excluded, the non-surgical treatment options are levothyroxine therapy and radioiodine ((131)I) therapy. Conventional (131)I therapy [without recombinant human thyroid-stimulating hormone (rhTSH)] has been used for more than a decade in symptomatic non...

UNLABELLED Patients with differentiated thyroid carcinoma (DTC) are treated with (131)I therapy after total thyroidectomy or surgical resection of recurrent tumor. However, some recurrent DTC lesions are not iodine-avid, which affects further treatment planning. The aim of this study was to evaluate the clinical benefit of (18)F-FDG PET/CT performed concurrently with (131)I therapy in DTC patie...

Therapy with radioiodine (I-131) has been used for patients with well-differentiated thyroid cancer such as papillary and follicular thyroid carcinoma to ablate normal thyroid tissue or to treat metastatic lesions. The improvement of survival rates and decrease of recurrence rates after I-131 therapy has been documented by retrospective studies (Mazzaferri & Jhiang, 1994; Samaan et al., 1992). ...

PURPOSE A multicenter, randomized study was undertaken to estimate the single agent activity of Tositumomab and to determine the contribution of radioisotope-labeling with (131)I to activity and toxicity by comparing treatment outcomes for Tositumomab and Iodine I 131 Tositumomab (BEXXAR) to an equivalent total dose of unlabeled Tositumomab. EXPERIMENTAL DESIGN Seventy-eight patients with ref...

Introduction:The maximum tolerable activity (MTA) of I-131 in radioiodine therapy is an established surrogate quantity to ensure that the therapeutic activity does not produce severe damages to the bone marrow and lung. The aim of this study was to estimate the MTAs for high-risk patients using I-124 pre-therapy dosimetry and to compare the results with published literature. <...